Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5.
Article PubMed Central PubMed Google Scholar
Kotecha K, Tree K, Ziaziaris WA, McKay SC, Wand H, Samra J, et al. Centralization of pancreaticoduodenectomy: a systematic review and spline regression analysis to recommend minimum volume for a specialist pancreas service. Ann Surg. 2024;279(6):953–60.
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Comprehens Cancer Netw JNCCN. 2017;15(8):1028–61.
Su Y-Y, Chao Y-J, Wang C-J, Liao T-K, Su P-J, Huang C-J, et al. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Int J Surg. 2023;109(9):2614–23.
Article PubMed Central PubMed Google Scholar
Zou Y, Gao S, Yu X, Zhou T, Xie Y, Guo X, et al. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study. Int J Surg. 2023;109(6):1573–83.
Article PubMed Central PubMed Google Scholar
Sugawara T, Rodriguez Franco S, Sherman S, Torphy RJ, Colborn K, Franklin O, et al. Neoadjuvant chemotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: an updated nationwide study. Ann Surg. 2024;279(2):331–9.
Ghanem I, Lora D, Herradón N, de Velasco G, Carretero-González A, Jiménez-Varas MÁ, et al. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. ESMO Open. 2022;7(3):100485.
Article PubMed Central CAS PubMed Google Scholar
Yang S-q, Zou R-q, Dai Y-s, Li F-y, Hu H-j. Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis. Updat Surg. 2024;76(1):1–15.
van Dam JL, Verkolf EMM, Dekker EN, Bonsing BA, Bratlie SO, Brosens LAA, et al. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023;23(1):728.
Article PubMed Central PubMed Google Scholar
Chawla A, Shi Q, Ko AH, Beg S, Varghese AM, Behrman SW, et al. Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. J Clin Oncol. 2023;41(16):TPS4204.
Brown ZJ, Heh V, Labiner HE, Brock GN, Ejaz A, Dillhoff M, et al. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Br J Surg. 2022;110(1):34–42.
Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–7.
Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu JK, et al. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci. 2023;30(1):111–21.
Hackert T, Klaiber U, Hinz U, Strunk S, Loos M, Strobel O, et al. Portal vein resection in pancreatic cancer surgery: risk of thrombosis and radicality determine survival. Ann Surg. 2023;277(6):e1291–8.
Bachellier P, Addeo P, Faitot F, Nappo G, Dufour P. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes? A single institution’s experience with 118 patients. Ann Surg. 2020;271(5):932–40.
Nigri G, Petrucciani N, Belloni E, Lucarini A, Aurello P, D’Angelo F, et al. Distal pancreatectomy with celiac axis resection: systematic review and meta-analysis. Cancers. 2021;13(8):1967.
Article PubMed Central PubMed Google Scholar
Loos M, Kester T, Klaiber U, Mihaljevic AL, Mehrabi A, Müller-Stich BM, et al. Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg. 2022;275(4):759–68.
De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery? A systematic review and meta-analysis. Cancers (Basel). 2020;12(11):3402.
Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: a review of current literature. Pancreatology. 2019;19(5):672–80.
Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, et al. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. 2017;265(2):397–401.
Hank T, Klaiber U, Hinz U, Schütte D, Leonhardt C-S, Bergmann F, et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. Ann Surg. 2023;277(5):e1089–98.
Gebauer F, Damanakis AI, Popp F, Quaas A, Kütting F, Lutz K, et al. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 2021;21(1):1239.
Article PubMed Central CAS PubMed Google Scholar
Wei M, Shi S, Hua J, Xu J, Yu X. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open. 2019;9(12):e033452.
Article PubMed Central PubMed Google Scholar
Wang M, Li D, Chen R, Huang X, Li J, Liu Y, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021;6(6):438–47.
Vissers FL, van Hilst J, Burdío F, Sabnis SC, Busch OR, Dijkgraaf MG, et al. Laparoscopic versus open pancreatoduodenectomy: an individual participant data meta-analysis of randomized controlled trials. HPB (Oxford). 2022;24(10):1592–9.
Wehrle CJ, Chang JH, Gross AR, Woo K, Naples R, Stackhouse KA, et al. Comparing oncologic and surgical outcomes of robotic and laparoscopic pancreatoduodenectomy in patients with pancreatic cancer: a propensity-matched analysis. Surg Endosc. 2024;38(5):2602–10.
Article PubMed Central PubMed Google Scholar
Da Dong X, Felsenreich DM, Gogna S, Rojas A, Zhang E, Dong M, et al. Robotic pancreaticoduodenectomy provides better histopathological outcomes as compared to its open counterpart: a meta-analysis. Sci Rep. 2021;11(1):3774.
Article PubMed Central PubMed Google Scholar
Kabir T, Tan HL, Syn NL, Wu EJ, Kam JH, Goh BKP. Outcomes of laparoscopic, robotic, and open pancreatoduodenectomy: a network meta-analysis of randomized controlled trials and propensity-score matched studies. Surgery. 2022;171(2):476–89.
Fu Y, Qiu J, Yu Y, Wu D, Zhang T. Meta-analysis of robotic versus open pancreaticoduodenectomy in all patients and pancreatic cancer patients. Front Surg. 2022;9:989065.
Article PubMed Central PubMed Google Scholar
Liu Q, Li M, Gao Y, Jiang T, Han B, Zhao G, et al. Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(5):428–37.
Cucchetti A, Bocchino A, Crippa S, Solaini L, Partelli S, Falconi M, et al. Advantages of laparoscopic distal pancreatectomy: Systematic review and meta-analysis of randomized and matched studies. Surgery. 2023;173(4):1023–9.
留言 (0)